Deputy Director of The Cordeliers Research Center - Head of the Physiopathology, Metabolism Department INSERM U1138 Team "Diabetes, metabolic diseases and comorbidities", France

President of the INSERM Specialized Scientific Committee Pathophysiology CSS3, President ECOS- Sud Committee and Coordinator Life Science


Frederic Jaisser got a permanent position as Director of Research at the National Institute of Health and Medical Research (INSERM) in 1996. Dr. Jaisser received his medical training and degrees from the Reims Medical School France and was qualified as Nephrologist in 1990. In 2003, he joined the Collège de France in Paris as an independent INSERM team and since 2009 he manages a team of the INSERM Unit U1138, at the Cordeliers Research Centre, Paris. He is Deputy Director of the Cordeliers Research Centre and Head of the “Pathophysiology, Metabolism” Department. Between 2010-2015, he was Scientific Delegate of the Pathophysiology Committee of the French National Research Agency. In 2020 he has been appointed as President of the ECOS French-South America exchange program and is particularly in charge of the Health projects between France and South America.

The aim of his studies is to improve the understanding of the pathophysiological roles and signaling pathways whereby the hormone aldosterone promotes pathologies in various organs including the kidney and the cardiovascular system but also eye skin and liver. His work combines cellular and molecular approaches, animal physiology, pharmacological
studies and has implications in human diseases. His interest includes translational research aimed to identify and validate biomarkers of Mineralocorticoid Receptor activation in cardiovascular and kidney diseases and novel therapeutic use of MR antagonists.

In the past years he focused his research on the impact of various MR antagonists, including the non-steroidal MRAs finerenone or KBP-5074 on the cardiovascular impact of chronic kidney disease and/or progression of renal failure. Current work analyzes the therapeutic benefit of the association of SGLT2i and MRAs in the cardiorenal field. He uncovered in collaboration with experts of skin or eye diseases a major benefit of topical or systemic MR antagonism in skin wound healing delay associated to dermocorticoids and diabetes or in age-related macular degeneration or diabetic retinopathy. He identified novel signaling pathways such as the Neutrophil Gelatinase-Associated Lipocalin as a major underlying mechanism in fibrotic and inflammatory consequences of MR activation in renal and cardiovascular diseases.



Part #2